Search alternatives:
mean decrease » a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
ns decrease » _ decrease (Expand Search), a decrease (Expand Search), use decreased (Expand Search)
mean decrease » a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
ns decrease » _ decrease (Expand Search), a decrease (Expand Search), use decreased (Expand Search)
-
4641
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”
-
4642
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”
-
4643
Initial treatment regimen.
Published 2024“…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
-
4644
Patients baseline characteristics.
Published 2024“…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
-
4645
Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles
Published 2025“…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
-
4646
Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles
Published 2025“…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
-
4647
Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles
Published 2025“…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
-
4648
Overall survival.
Published 2024“…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
-
4649
Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles
Published 2025“…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
-
4650
CHWs house visits.
Published 2024“…The performance of the malaria CHW network was evaluated using weekly data collected from CHWs and routinely collected surveillance data from the Ministry of Public Health (MoH). We assess performance of CHWs by analyzing key variables including (1) reporting compliance, (2) household visitation rates, (3) malaria rapid diagnostic tests performed, (4) malaria cases detected, and (5) time between symptom onset and malaria diagnosis. …”
-
4651
Progression-free survival by treatment.
Published 2024“…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
-
4652
Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles
Published 2025“…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
-
4653
Maintenance regimen and adverse event management.
Published 2024“…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
-
4654
Charge-Transfer-Driven Electrical Conductivity in Single Crystals of Assembled Triphenylamine Bis-urea Macrocycles
Published 2025“…By encapsulating guests with varying reduction potentials, including 2,5-dichloro-1,4-benzoquinone (ClBQ), 2,1,3-benzothiadiazole (BTD), and malononitrile (MN), we observed significant changes in the electrical conductivity. …”
-
4655
BCC-specific survival.
Published 2024“…We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). …”
-
4656
Optical coherence tomography findings.
Published 2024“…After PCI, hDPV significantly increased from 55.6 cm/s to 69.5 cm/s (P<0.01), with a median %hDPV increase of 27.2 (6.32–59.1) %, while %hDPV decreased in 20 (19.4%) patients. …”
-
4657
S1 Data -
Published 2024“…After PCI, hDPV significantly increased from 55.6 cm/s to 69.5 cm/s (P<0.01), with a median %hDPV increase of 27.2 (6.32–59.1) %, while %hDPV decreased in 20 (19.4%) patients. …”
-
4658
Clinical demographics and angiographic findings.
Published 2024“…After PCI, hDPV significantly increased from 55.6 cm/s to 69.5 cm/s (P<0.01), with a median %hDPV increase of 27.2 (6.32–59.1) %, while %hDPV decreased in 20 (19.4%) patients. …”
-
4659
Physiological parameters.
Published 2024“…After PCI, hDPV significantly increased from 55.6 cm/s to 69.5 cm/s (P<0.01), with a median %hDPV increase of 27.2 (6.32–59.1) %, while %hDPV decreased in 20 (19.4%) patients. …”
-
4660